| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
CD40L-induced NF-κB activation in CD40 sensor cells is concentration-dependently inhibited by DRI-C21045 (3.2-100 μM; 18 h) [1]. Primary B cells' CD40L-induced functional activation is blocked by DRI-C21045 (0.6–50 μM; 48 hours) [1]. In THP-1 cells, CD40L-induced MHC-II upregulation is inhibited by DRI-C21045 (0.4-50 μM; 48 hours) [1]. The 48-hour DRI-C21045 (2-100 μM) inhibits the proliferation of B cells induced by CD40L [1]. At concentrations of up to 500 µM, DRI-C21045 exhibits no potential genotoxicity and no indications of cytotoxicity [1].
|
|---|---|
| ln Vivo |
In a mouse skin allograft model, DRI-C21045 (30 mg/kg; daily, subcutaneous; in 20% HPβCD) prolongs graft life [1]. In draining lymph nodes (DLN), DRI-C21045 (20–60 mg/kg; subcutaneous injection twice daily; dissolved in 20% HPβCD) suppresses T cell growth induced by alloantigen [1].
|
| Animal Protocol |
Animal/Disease Models: Full-thickness ear skin transplantation from BALB/c to dorsal thorax of C57BL/6 [1]
Doses: 30 mg/kg Route of Administration: daily subcutaneous injection; in 20% w/v hydroxypropyl-β-cyclo Administration of dextrin (HPβCD) in solution resulted in prolonged skin allograft survival. |
| References |
|
| Molecular Formula |
C32H24N2O7S
|
|---|---|
| Molecular Weight |
580.607167243958
|
| Exact Mass |
580.13
|
| CAS # |
2101765-81-3
|
| PubChem CID |
129275747
|
| Appearance |
Off-white to gray solid powder
|
| LogP |
5.1
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
42
|
| Complexity |
1050
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C1C=CC=C2C=CC=C(C2=1)NC(C1C=CC(=CC=1)C1C=CC(=CC=1)NC(C1C=CC(C(=O)OC)=CC=1)=O)=O)(=O)(=O)O
|
| InChi Key |
BZAWLSZPOBGURT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C32H24N2O7S/c1-41-32(37)25-14-12-23(13-15-25)30(35)33-26-18-16-21(17-19-26)20-8-10-24(11-9-20)31(36)34-27-6-2-4-22-5-3-7-28(29(22)27)42(38,39)40/h2-19H,1H3,(H,33,35)(H,34,36)(H,38,39,40)
|
| Chemical Name |
8-[[4-[4-[(4-methoxycarbonylbenzoyl)amino]phenyl]benzoyl]amino]naphthalene-1-sulfonic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~2 mg/mL (~3.44 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 0.5 mg/mL (0.86 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7223 mL | 8.6116 mL | 17.2233 mL | |
| 5 mM | 0.3445 mL | 1.7223 mL | 3.4447 mL | |
| 10 mM | 0.1722 mL | 0.8612 mL | 1.7223 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
